• Profile
Close
Sign Up / Log In
Journal Summaries
Endocrinology
  Pharmacology/kinetics

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial

The Lancet Diabetes & Endocrinology | Oct 25, 2021 Pharmacology/kinetics

Tirzepatide vs insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomized, open-label, parallel-group, multicentre, phase 3 trial

The Lancet | Oct 24, 2021 Pharmacology/kinetics

Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia

Journal of Clinical Endocrinology and Metabolism | Oct 18, 2021 Pharmacology/kinetics

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis

Diabetes, Obesity and Metabolism | Oct 16, 2021 Pharmacology/kinetics

Oral calcitriol use, vertebral fractures, and vitamin K in hemodialysis patients: A cross‐sectional study

Journal of Bone and Mineral Research | Oct 14, 2021 Pharmacology/kinetics

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death

Cardiovascular Diabetology | Oct 10, 2021 Pharmacology/kinetics

Association between novel glucose-lowering drugs and risk of asthma: A network meta-analysis of cardiorenal outcome trials

Diabetes Research and Clinical Practice | Oct 09, 2021 Pharmacology/kinetics

Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in individuals with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism | Oct 08, 2021 Pharmacology/kinetics

Factors associated with the degree of glycemic deterioration among patients with type 2 diabetes who dropped out of diabetes care: A longitudinal analysis using medical claims and health checkup data in Japan

Journal of Diabetes Investigation | Oct 08, 2021 Pharmacology/kinetics

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Diabetes, Obesity and Metabolism | Oct 08, 2021 Pharmacology/kinetics

1 … 8 10 12 … 122
Most read this week
1

MD Clip on Recent Advances in Lipid Management with Dr Gopinath
Placeholder
2

Article: Anti-Inflammatory Diets for Pain and Arthritis Management
Placeholder
3

Article on Strategies to Reduce Antibiotic Misuse and Address Antimicrobial Resistance

Placeholder
4

The 1 food geriatricians avoid to live a long, healthy life
5

Many young adults have high long-term risk for cardiovascular disease, study finds
Bannerimg

A variety of information related to Medicine and Health Care. It's all here.

Select Topic

x
M3 app logo
Choose easy access to M3 India from your mobile!

Add to home

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay